Skip to main content
Fig. 1 | BMC Nephrology

Fig. 1

From: Microangiopathy in multiple myeloma: a case of carfilzomib-induced secondary thrombotic microangiopathy successfully treated with plasma exchange and complement inhibition

Fig. 1

Creatinine(blue) and eGFR (CKD-EPI; ml/min/1.73m2) course of the patient over the duration of 56 days after diagnosis. Treatment with plasmapheresis is indicated with black arrows and treatment with eculizumab (first four doses of 900 mg and following doses of 1200 mg) is indicated with green arrows

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us